APHEXDA (motixafortide acetate)
Aphexda helps patients with multiple myeloma by moving hematopoietic stem cells from the bone marrow into the bloodstream. It is used in combination with filgrastim to prepare these cells for collection and later autologous transplantation. This process ensures that a sufficient number of stem cells are available in the peripheral blood to be harvested for the patient's treatment.
How APHEXDA Works
This drug works by blocking the CXCR4 receptor, which prevents it from binding to a signaling molecule that normally anchors stem cells inside the bone marrow matrix. By interrupting this bond, the medication triggers the release of hematopoietic stem and progenitor cells into the peripheral circulation. This results in an increase of circulating cells that can then be effectively collected for transplantation.
Details
- Status
- Prescription
- First Approved
- 2023-09-08
- Patent Cliff
- 2041
- Routes
- SUBCUTANEOUS
- Dosage Forms
- POWDER
APHEXDA Approval History
What APHEXDA Treats
1 indicationsAPHEXDA is approved for 1 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Multiple Myeloma
APHEXDA Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in APHEXDA's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications APHEXDA treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to APHEXDA
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
APHEXDA FDA Label Details
Indications & Usage
FDA Label (PDF)APHEXDA is indicated for the treatment of Multiple Myeloma.
APHEXDA Patents & Exclusivity
Patents (2 active)
Exclusivity
Pro Intelligence Preview
Deep insights for APHEXDA
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2041
- • 2 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.